HUANG, SHANSHAN
 Distribuzione geografica
Continente #
AS - Asia 136
NA - Nord America 67
EU - Europa 40
AF - Africa 6
SA - Sud America 5
Totale 254
Nazione #
VN - Vietnam 74
US - Stati Uniti d'America 67
SG - Singapore 21
HK - Hong Kong 15
CN - Cina 10
DE - Germania 9
SE - Svezia 9
IN - India 8
GB - Regno Unito 6
TG - Togo 5
FR - Francia 3
IE - Irlanda 3
JP - Giappone 3
BR - Brasile 2
FI - Finlandia 2
IT - Italia 2
RU - Federazione Russa 2
AR - Argentina 1
CO - Colombia 1
CZ - Repubblica Ceca 1
EC - Ecuador 1
ET - Etiopia 1
HR - Croazia 1
IL - Israele 1
PH - Filippine 1
PL - Polonia 1
TR - Turchia 1
TW - Taiwan 1
UA - Ucraina 1
UZ - Uzbekistan 1
Totale 254
Città #
Ho Chi Minh City 23
Hanoi 21
Hong Kong 14
Ashburn 11
Singapore 10
Chandler 6
Southend 6
Haiphong 5
Lomé 5
San Jose 5
Da Nang 4
Los Angeles 4
Princeton 4
Redmond 4
Biên Hòa 3
Dublin 3
Boardman 2
Fairfield 2
Hangzhou 2
Helsinki 2
Lauterbourg 2
Medford 2
Nuremberg 2
Phú Nhuận 2
Pune 2
Tokyo 2
Addis Ababa 1
Ann Arbor 1
Beijing 1
Brno 1
Brooklyn 1
Buffalo 1
Concordia 1
Des Moines 1
Falkenstein 1
Guarujá 1
Houston 1
Huế 1
Hyderabad 1
Hải Dương 1
Mohyliv-Podilskyi 1
Munich 1
New York 1
Ninh Bình 1
Olalla 1
Pearland 1
Phoenix 1
Phúc Thọ 1
Quito 1
Quận Hai 1
San Diego 1
Santa Clara 1
Santa Marta 1
Selçuklu 1
Shijiazhuang 1
São Paulo 1
Taichung 1
Tashkent 1
Thu Dau Mot 1
Thái Nguyên 1
Tolland 1
Tân Tiến 1
Việt Trì 1
Warsaw 1
Wilmington 1
Wuhu 1
Wuxi 1
Zagreb 1
Totale 190
Nome #
Corrigendum to “Rondeau E, Scully M, Ariceta G, Barbour T, Cataland S, Heyne N, Miyakawa Y, Ortiz S, Swenson E, Vallee M, Yoon S-S, Kavanagh D and Haller H; on behalf of the 311 Study Group. The long-acting C5 inhibitor, Ravulizumab, is effective and safe in adult patients with atypical hemolytic uremic syndrome naïve to complement inhibitor treatment.” Kidney Int. 2020;97:1287–1296 (Kidney International (2020) 97(6) (1287–1296), (S0085253820301526), (10.1016/j.kint.2020.01.035)) 170
Erratum to “Rondeau E, Scully M, Ariceta G, Barbour T, Cataland S, Heyne N, Miyakawa Y, Ortiz S, Swenson E, Vallee M, Yoon S-S, Kavanagh D, Haller H; on behalf of the 311 Study Group. The long-acting C5 inhibitor, Ravulizumab, is effective and safe in adult patients with atypical hemolytic uremic syndrome naïve to complement inhibitor treatment” Kidney Int. 2020;97:1287–1296 (Kidney International (2020) 97(6) (1287–1296), (S0085253820301526), (10.1016/j.kint.2020.01.035)) 87
Totale 257
Categoria #
all - tutte 881
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 881


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20215 0 0 0 0 0 0 0 0 0 0 0 5
2021/202236 0 1 2 8 5 2 0 1 2 3 7 5
2022/202333 2 4 3 2 3 4 3 4 7 1 0 0
2023/20247 0 2 1 0 0 2 0 0 0 0 0 2
2024/202535 1 2 3 1 2 2 5 2 0 1 0 16
2025/2026141 8 3 5 3 7 8 75 2 20 8 2 0
Totale 257